Perdonà S, Autorino R, De Placido S, D’Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco AR, Di Lorenzo G (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol.;6(5):295–300. https://doi.org/10.1016/S1470-2045(05)70103-0. PMID: 15863377

Mallah H, Diabasana Z, Soultani S, Idoux-Gillet Y, Massfelder T (2025) Prostate cancer: A journey through its history and recent developments. Cancers (Basel) 17(2):194. https://doi.org/10.3390/cancers17020194PMID: 39857976; PMCID: PMC11763992

Article  CAS  PubMed  Google Scholar 

Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, Bollina P, Doble A, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Paez E, Powell P, Rosario DJ, Rowe E, Mason M, Catto JWF, Peters TJ, Oxley J, Williams NJ, Staffurth J, Neal DE (2023) ProtecT Study Group. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med.;388(17):1547–1558. https://doi.org/10.1056/NEJMoa2214122. Epub 2023 Mar 11. PMID: 36912538

Wang F, Fan Y, Yin X, Qi LW, Ma G, Yuan Q (2021) Prognostic comparison between radical prostatectomy and radiotherapy in prostate cancer patients at different stages and ages. Aging 13(12):16773–16785. https://doi.org/10.18632/aging.203198Epub 2021 Jun 29. PMID: 34185023; PMCID: PMC8266375

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iversen P (2002) Antiandrogen monotherapy: indications and results. Urology.;60(3 Suppl 1):64–71. https://doi.org/10.1016/s0090-4295(02)01576-5. PMID: 12231053

Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F (2005) Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol.;23(4):808– 15. https://doi.org/10.1200/JCO.2005.12.013. PMID: 15681525

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148–163. https://doi.org/10.1016/j.eururo.2024.03.027Epub 2024 Apr 13. PMID: 38614820

Article  PubMed  Google Scholar 

See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T (2003) Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol.;44(5):512-7; discussion 517-8. https://doi.org/10.1016/s0302-2838(03)00366-x. PMID: 14572747

Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K (2004) Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol.;172(5 Pt 1):1865-70. https://doi.org/10.1097/01.ju.0000140159.94703.80. PMID: 15540740

See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ, Casodex Early Prostate Cancer Trialist Group (2002). Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol.;168(2):429– 35. Erratum in: J Urol 2002;168(6):2558. Erratum in: J Urol 2002;168;4(Pt 1):1510. PMID: 12131282

Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP (2010) Casodex Early Prostate Cancer Trialists’ Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int.;105(8):1074-81. https://doi.org/10.1111/j.1464-410X.2010.09319.x. PMID: 22129214

National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: [Prostate Cancer] Version [3.2024]. 2024. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Fizazi K, Gillessen S, ESMO Guidelines Committee (2023) Electronic address: clinicalguidelines@esmo.org. Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents. Ann Oncol 34(6):557–563 Epub 2023 Mar 21. PMID: 36958590

Article  CAS  PubMed  Google Scholar 

Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders JLH, Liew G, Linares Espinos M, Oldenburg E, van Oort J, Oprea-Lager IM, Ploussard DE, Roberts G, Rouvière MJ, Schoots O, Schouten IG, Smith N, Stranne EJ, Wiegel J, Willemse T, Cornford PM (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86(2):164–182. https://doi.org/10.1016/j.eururo.2024.04.010Epub 2024 Apr 29. PMID: 38688773

Article  CAS  PubMed  Google Scholar 

Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, Zamboglou C, Mohamad O, Aebersold DM, Cathomas R (2024) Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate Cancer Prostatic Dis 27(3):422–431. https://doi.org/10.1038/s41391-024-00829-9Epub 2024 Apr 8. PMID: 38589645; PMCID: PMC11319196

Article  PubMed  PubMed Central  Google Scholar 

Barros AC, Sampaio Mde C (2012) Gynecomastia: physiopathology, evaluation and treatment. Sao Paulo Med J 130(3):187–197. https://doi.org/10.1590/s1516-31802012000300009PMID: 22790552; PMCID: PMC10876201

Article  PubMed  PubMed Central  Google Scholar 

Wilson JD, Aiman J, MacDonald PC (1980) The pathogenesis of gynecomastia. Adv Intern Med 25:1–32 PMID: 6987837

CAS  PubMed  Google Scholar 

Mathur R, Braunstein GD (1997) Gynecomastia: pathomechanisms and treatment strategies. Horm Res.;48(3):95–102. https://doi.org/10.1159/000185497. PMID: 11546925

Fagerlund A, Cormio L, Palangi L, Lewin R, Santanelli di Pompeo F, Elander A, Selvaggi G (2015) Gynecomastia in patients with prostate cancer: A systematic review. PLoS ONE 10(8):e0136094. https://doi.org/10.1371/journal.pone.0136094PMID: 26308532; PMCID: PMC4550398

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B, Gynecomastia (2014) Clinical evaluation and management. Indian J Endocrinol Metab 18(2):150–158. https://doi.org/10.4103/2230-8210.129104PMID: 24741509; PMCID: PMC3987263

Article  PubMed  PubMed Central  Google Scholar 

Sieber PR (2007) Treatment of bicalutamide-induced breast events. Expert Rev Anticancer Ther.;7(12):1773-9. https://doi.org/10.1586/14737140.7.12.1773. PMID: 18062751

Swerdloff RS, Ng JCM, Gynecomastia: Etiology, Diagnosis (2023) and Treatment. Jan 6. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905330

Tyrrell CJ (1999) Gynaecomastia: aetiology and treatment options. Prostate Cancer Prostatic Dis.;2(4):167–171. https://doi.org/10.1038/sj.pcan.4500314. PMID: 12496773

Di Lorenzo G, Perdonà S, De Placido S, D’Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R (2005) Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol.;174(6):2197– 203. https://doi.org/10.1097/01.ju.0000181824.28382.5c. PMID: 16280763

Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S (2007) Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol.;52(1):106– 14. doi: 10.1016/j.eururo.2007.01.031. Epub 2007 Jan 16. PMID: 17270340

Saltzstein D, Sieber P, Morris T, Gallo J (2005) Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis.;8(1):75–83. https://doi.org/10.1038/sj.pcan.4500782. PMID: 15685254

Serretta V, Altieri V, Morgia G, Nicolosi F, De Grande G, Mazza R, Melloni D, Allegro R, Ferraù F, Gebbia V (2012) A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer.;10(3):174-9. doi: 10.1016/j.clgc.2012.03.002. Epub 2012 Apr 12. PMID: 22502790

Ozen H, Akyol F, Toktas G, Eskicorapci S, Unluer E, Kuyumcuoglu U, Abay E, Cureklibatur I, Sengoz M, Yalcin V, Akpinar H, Zorlu F, Sengor F, Karaman I (2010) Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain? J Urol 184(2):519–524 Epub 2010 Jun 17. PMID: 20620411

Article  PubMed  Google Scholar 

Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K (2004) Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys.;60(2):476– 83. https://doi.org/10.1016/j.ijrobp.2004.03.022. PMID: 15380582

Widmark A, Fosså SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O (2003) Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology.;61(1):145– 51. https://doi.org/10.1016/s0090-4295(02)02107-6. PMID: 12559286

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Wiegel T, Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO), The Working Party Radiation Oncology of the German Cancer Society (DKG-ARO) (2020) Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer. Strahlenther Onkol 196(7):589–597. https://doi.org/10.1007/s00066-020-01598-9Epub 2020 Mar 12. PMID: 32166452; PMCID: PMC7305090

Article  PubMed  PubMed Central  Google Scholar 

Tunio MA, Al-Asiri M, Al-Amro A, Bayoumi Y, Fareed M (2012) Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis. Curr Oncol 19(4):e280–e288. https://doi.org/10.3747/co.19.993PMID: 22876157; PMCID: PMC3410840

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https://doi.org/10.1186/2046-4053-4-1

Article  PubMed  PubMed Central  Google Scholar 

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12

Article  CAS  PubMed  Google Scholar 

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. StatMed 21:1539–1558

Google Scholar 

Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304):101–105. https://doi.org/10.1136/bmj.323.7304.101PMID: 11451790; PMCID: PMC1120714

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duval SJ, Tweedie RL (2000) A non-parametric trim and fill method of assessing publication bias in meta-analysis. J Am Stat Assoc 95:89–98

Google Scholar 

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S, ESMO Guidelines Committee (2020) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9):1119–1134. https://doi.org/10.1016/j.annonc.2020.06.011

Article  CAS  PubMed  Google Scholar 

Cornford P, Tilki D, van den Bergh RCN et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer– Limited Update April 2024. Eur Urol. Available at: https://uroweb.org/guideline/prostate-cancer. Accessed March 12, 2025

Tsuboi I, Schulz RJ, Laukhtina E, Wada K, Karakiewicz PI, Araki M, Shariat SF (2025) Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: A systematic review and Meta-analysis of randomized controlled trials. Eur Urol Open Sci 73:31–42 PMID: 39935942; PMCID: PMC11810703

Article  PubMed  PubMed Central  Google Scholar 

Huggins C, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43(5):709–723

Google Scholar 

Han BH, Lim JS, Kim SW (2013) Low-dose radiotherapy in the treatment of gynecomastia induced by antiandrogen therapy. Int J Radiat Oncol Biol Phys 87(5):950–956

Google Scholar 

Santen RJ, Mansel R, Goldstein L (2010) The role of aromatase inhibitors in gynecomastia prevention. Lancet Oncol 11(10):855–864